Symptoms in patients on long‐term proton pump inhibitors: prevalence and predictors
Open Access
- 8 January 2009
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (4) , 431-439
Abstract
Summary: Background Symptom control in primary care patients on long‐term proton pump inhibitor (PPI) treatment is poorly understood.Aim To explore associations between symptom control and demographics, lifestyle, PPI use, diagnosis and Helicobacter pylori status.Methods A cross‐sectional survey (n = 726) using note reviews, questionnaires and carbon‐13 urea breath testing. Determinants of symptom control [Leeds Dyspepsia Questionnaire (LDQ), Carlsson and Dent Reflux Questionnaire (CDRQ), health‐related quality‐of‐life measures (EuroQoL: EQ‐5D and EQ‐VAS)] were explored using stepwise linear regression.Results Moderate or severe dyspepsia symptoms occurred in 61% of subjects (LDQ) and reflux symptoms in 59% (CDRQ). Age, gender, smoking and body mass index had little or no influence upon symptom control or PPI use. Average symptom scores and PPI use were lower in patients with non‐ulcer dyspepsia and gastro‐protection than gastro‐oesophageal reflux disease (GERD) and uninvestigated dyspepsia. H. pylori infection was associated with lower reflux symptom scores only in patients with GERD and uninvestigated dyspepsia. EQ‐5D was not able to discriminate between diagnostic groups, although the EQ‐VAS performed well.Conclusions A majority of patients suffered ongoing moderate or severe symptoms. GERD and uninvestigated dyspepsia were associated with poorer long‐term symptom control; H. pylori appeared to have a protective effect on reflux symptoms in these patients.Keywords
This publication has 25 references indexed in Scilit:
- Helicobacter pylori eradication in long‐term proton pump inhibitor users in primary care: a randomized‐controlled trialAlimentary Pharmacology & Therapeutics, 2006
- Review article: the long‐term use of proton‐pump inhibitorsAlimentary Pharmacology & Therapeutics, 2005
- Review article: gastro‐oesophageal reflux disease – the health economic implicationsAlimentary Pharmacology & Therapeutics, 2005
- cagA-positive Helicobacter pylori strains and gastro-oesophageal reflux diseaseEuropean Journal of Gastroenterology & Hepatology, 2004
- Patient‐directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trialAlimentary Pharmacology & Therapeutics, 2004
- Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic reviewBMJ, 2003
- Who is using chronic acid suppression therapy and why?American Journal of Gastroenterology, 2003
- The prevalence of dyspepsia and use of antisecretory medication in North Glasgow: role of Helicobacter pylori vs. lifestyle factorsAlimentary Pharmacology & Therapeutics, 1999
- Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research DatabaseBMJ, 1998
- Determinants of prescribing costs for ulcer-healing drugs and upper gastrointestinal endoscopy in general practiceEuropean Journal of Gastroenterology & Hepatology, 1998